Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 23Neoplasm Metastasis 14Leukemia, Myeloid, Acute 11Carcinoma, Renal Cell 10Neoplasms 8Kidney Neoplasms 8Skin Neoplasms 5Recurrence 5Leukemia 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neuroblastoma 3Lymphoma, Follicular 3Congenital Abnormalities 3Carcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2

Interventions

Rituximab 24Cyclophosphamide 14fludarabine 8Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5fludarabine phosphate 4Carboplatin 4venetoclax 3obinutuzumab 3ibrutinib 3atezolizumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Cytarabine 3Carmustine 3Bortezomib 3Bendamustine Hydrochloride 3ublituximab 2pembrolizumab 2pegfilgrastim 2ibritumomab tiuxetan 2Tiragolumab 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Indium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell × Interleukin-2 × Clear all
NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

Fate Therapeutics

Phase 1 Terminated
72 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡